Search for other papers by Hui Li in
Google Scholar
PubMed
Search for other papers by Peng Wu in
Google Scholar
PubMed
various diseases, including thyroid cancer ( 3 , 4 ). This regulation includes DNA methylation, chromatin remodeling, histone modifications, and the expression of diverse non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long ncRNAs (lncRNAs), and
Search for other papers by Sara Ahmadi in
Google Scholar
PubMed
Search for other papers by Iñigo Landa in
Google Scholar
PubMed
Introduction Thyroid cancer is the most common malignancy of the endocrine system. Papillary thyroid carcinoma (PTC) is the most common thyroid carcinoma, accounting for almost 80% of cases; 12% of thyroid carcinomas have follicular (FTC) or
Division of Endocrinology, Department of Medicine, Medstar Washington Hospital Center, Washington Hospital Center, Northwest, Washington, District of Columbia, USA
Search for other papers by Joanna Klubo-Gwiezdzinska in
Google Scholar
PubMed
Search for other papers by John Costello Jr in
Google Scholar
PubMed
Search for other papers by Kirk Jensen in
Google Scholar
PubMed
Search for other papers by Aneeta Patel in
Google Scholar
PubMed
Search for other papers by Rok Tkavc in
Google Scholar
PubMed
Search for other papers by Douglas Van Nostrand in
Google Scholar
PubMed
Search for other papers by Kenneth D Burman in
Google Scholar
PubMed
Search for other papers by Leonard Wartofsky in
Google Scholar
PubMed
Search for other papers by Vasyl Vasko in
Google Scholar
PubMed
Introduction Standard treatment of thyroid cancer consists of surgical resection and radioiodine ( 131 I) therapy ( 1 ). Depending on the risk stratification of the individual patient, the primary goal of the application of radioactive iodine
Search for other papers by Zeming Liu in
Google Scholar
PubMed
Search for other papers by Di Hu in
Google Scholar
PubMed
Search for other papers by Yihui Huang in
Google Scholar
PubMed
Search for other papers by Sichao Chen in
Google Scholar
PubMed
Search for other papers by Wen Zeng in
Google Scholar
PubMed
Search for other papers by Ling Zhou in
Google Scholar
PubMed
Search for other papers by Wei Zhou in
Google Scholar
PubMed
Search for other papers by Min Wang in
Google Scholar
PubMed
Search for other papers by Haifeng Feng in
Google Scholar
PubMed
Search for other papers by Wei Wei in
Google Scholar
PubMed
Search for other papers by Chao Zhang in
Google Scholar
PubMed
Search for other papers by Danyang Chen in
Google Scholar
PubMed
Search for other papers by Liang Guo in
Google Scholar
PubMed
carcinoma. Among pediatric patients, papillary thyroid carcinoma and follicular thyroid cancer account for more than 90% ( 2 ) of all childhood cases. However, medulary thyroid cancer, poorly differentiated tumors and undifferentiated (anaplastic) thyroid
Search for other papers by Sara Ahmadi in
Google Scholar
PubMed
Search for other papers by Alexandra Coleman in
Google Scholar
PubMed
Endocrinology Service, Instituto Nacional de Câncer, Rio de Janeiro, Brazil
Search for other papers by Nathalie Silva de Morais in
Google Scholar
PubMed
Search for other papers by Iñigo Landa in
Google Scholar
PubMed
Search for other papers by Theodora Pappa in
Google Scholar
PubMed
Search for other papers by Alex Kang in
Google Scholar
PubMed
Search for other papers by Matthew I Kim in
Google Scholar
PubMed
Search for other papers by Ellen Marqusee in
Google Scholar
PubMed
Search for other papers by Erik K Alexander in
Google Scholar
PubMed
Introduction The past two decades have witnessed a dramatic rise in the incidence of newly diagnosed thyroid cancer ( 1 ), primarily attributable to the detection of incidental or small-volume disease. Simultaneous to this, practitioners have
Search for other papers by Zherui Fu in
Google Scholar
PubMed
Search for other papers by Yi Lai in
Google Scholar
PubMed
Search for other papers by Qianfei Wang in
Google Scholar
PubMed
Search for other papers by Feng Lin in
Google Scholar
PubMed
Search for other papers by Jiaping Fang in
Google Scholar
PubMed
Introduction Thyroid cancer is one of the most common malignant tumors of the endocrine system, accounting for 2% of all malignant tumors. The incidence of thyroid cancer has rapidly increased in recent decades, which is a significant concern
Division of General Medicine, Istituto Auxologico Italiano, IRCCS, S. Giuseppe Hospital, Piancavallo di Oggebbio (VB), Italy
Search for other papers by Chiara Mele in
Google Scholar
PubMed
Search for other papers by Maria Teresa Samà in
Google Scholar
PubMed
Search for other papers by Alessandro Angelo Bisoffi in
Google Scholar
PubMed
Search for other papers by Marina Caputo in
Google Scholar
PubMed
Search for other papers by Valentina Bullara in
Google Scholar
PubMed
Search for other papers by Stefania Mai in
Google Scholar
PubMed
Search for other papers by Gillian Elisabeth Walker in
Google Scholar
PubMed
Search for other papers by Flavia Prodam in
Google Scholar
PubMed
Division of General Medicine, Istituto Auxologico Italiano, IRCCS, S. Giuseppe Hospital, Piancavallo di Oggebbio (VB), Italy
Search for other papers by Paolo Marzullo in
Google Scholar
PubMed
Search for other papers by Gianluca Aimaretti in
Google Scholar
PubMed
Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy
Search for other papers by Loredana Pagano in
Google Scholar
PubMed
Introduction The incidence rates of differentiated thyroid cancer (DTC) have been rising in many countries over the last few decades ( 1 , 2 ) along with a parallel increase in obesity and metabolic disorders ( 3 ). Even if the growing
Search for other papers by Jiwen Yang in
Google Scholar
PubMed
Search for other papers by Yayin Huang in
Google Scholar
PubMed
Search for other papers by Bohan Dong in
Google Scholar
PubMed
Search for other papers by Yunhai Dai in
Google Scholar
PubMed
Highlights lncRNA DLEU2 is significantly upregulated in thyroid cancer tissues and cell lines. DLEU2 accelerates the proliferation, migration and aerobic glycolysis while inhibits the apoptosis of thyroid cancer cells. miR-205
Search for other papers by Meihua Jin in
Google Scholar
PubMed
Search for other papers by Woo Kyung Lee in
Google Scholar
PubMed
Search for other papers by Mi-Hyeon You in
Google Scholar
PubMed
Search for other papers by Ahreum Jang in
Google Scholar
PubMed
Search for other papers by Sheue-yann Cheng in
Google Scholar
PubMed
Search for other papers by Won Gu Kim in
Google Scholar
PubMed
Search for other papers by Min Ji Jeon in
Google Scholar
PubMed
Search for other papers by Yu-Mi Lee in
Google Scholar
PubMed
cancer cells to maintain rapid cell proliferation, tumor progression, and resistance to cell death ( 2 , 3 ). However, metabolic reprogramming in thyroid cancers is not well known. In a previous study, we uncovered that phosphoglycerate dehydrogenase
Search for other papers by M L Gild in
Google Scholar
PubMed
Search for other papers by M Bullock in
Google Scholar
PubMed
Search for other papers by C K Pon in
Google Scholar
PubMed
Cancer Genetics Laboratory, Department of Endocrinology, Kolling Institute of Medical Research, Sydney, New South Wales, Australia
Search for other papers by B G Robinson in
Google Scholar
PubMed
Cancer Genetics Laboratory, Department of Endocrinology, Kolling Institute of Medical Research, Sydney, New South Wales, Australia
Search for other papers by R J Clifton-Bligh in
Google Scholar
PubMed
including prostate (9) , non small cell lung cancer (10) , and osteosarcoma (11) . With regard to thyroid cancer, early studies have yielded data that supports the potential clinical utility of targeting HSP90 to treat this disease. 17-AAG has showed an